Search details
1.
Preclinical evaluation of a novel CAR-T therapy utilizing a scFv antibody highly specific to MAGE-A4p230-239/HLA-A∗02:01 complex.
Mol Ther
; 32(3): 734-748, 2024 Mar 06.
Article
in English
| MEDLINE | ID: mdl-38243600
2.
A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma.
Int J Cancer
; 152(12): 2554-2566, 2023 06 15.
Article
in English
| MEDLINE | ID: mdl-36727538
3.
[Exploring for the Development of Personalized Cancer Immunotherapy].
Gan To Kagaku Ryoho
; 50(5): 567-570, 2023 May.
Article
in Japanese
| MEDLINE | ID: mdl-37218313
4.
Prognostic significance of NY-ESO-1 antigen and PIGR expression in esophageal tumors of CHP-NY-ESO-1-vaccinated patients as adjuvant therapy.
Cancer Immunol Immunother
; 71(11): 2743-2755, 2022 Nov.
Article
in English
| MEDLINE | ID: mdl-35429246
5.
IL-17A Is the Critical Cytokine for Liver and Spleen Amyloidosis in Inflammatory Skin Disease.
Int J Mol Sci
; 23(10)2022 May 20.
Article
in English
| MEDLINE | ID: mdl-35628531
6.
Relationship between T cell receptor clonotype and PD-1 expression of tumor-infiltrating lymphocytes in colorectal cancer.
Eur J Immunol
; 50(10): 1580-1590, 2020 10.
Article
in English
| MEDLINE | ID: mdl-32441316
7.
Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients.
Cancer Immunol Immunother
; 70(11): 3081-3091, 2021 Nov.
Article
in English
| MEDLINE | ID: mdl-33751208
8.
Development of INSOL-tag for proteome-wide protein handling and its application in protein array analysis.
Genes Cells
; 25(1): 41-53, 2020 Jan.
Article
in English
| MEDLINE | ID: mdl-31733161
9.
First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors.
Cancer Immunol Immunother
; 69(4): 663-675, 2020 Apr.
Article
in English
| MEDLINE | ID: mdl-31980914
10.
Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination.
Blood
; 132(11): 1134-1145, 2018 09 13.
Article
in English
| MEDLINE | ID: mdl-30045840
11.
MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours.
BMC Cancer
; 20(1): 606, 2020 Jun 29.
Article
in English
| MEDLINE | ID: mdl-32600281
12.
Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS.
Blood
; 130(18): 1985-1994, 2017 11 02.
Article
in English
| MEDLINE | ID: mdl-28860210
13.
PD-1-dependent restoration of self-tolerance in the NOD mouse model of diabetes after transient anti-TCRß mAb therapy.
Diabetologia
; 58(6): 1309-18, 2015 Jun.
Article
in English
| MEDLINE | ID: mdl-25794782
14.
A dynamic dual role of IL-2 signaling in the two-step differentiation process of adaptive regulatory T cells.
J Immunol
; 190(7): 3153-62, 2013 Apr 01.
Article
in English
| MEDLINE | ID: mdl-23427250
15.
Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients.
J Transl Med
; 11: 246, 2013 Oct 05.
Article
in English
| MEDLINE | ID: mdl-24093426
16.
Fully closed cell sorter for immune cell therapy manufacturing.
Mol Ther Methods Clin Dev
; 30: 367-376, 2023 Sep 14.
Article
in English
| MEDLINE | ID: mdl-37637381
17.
Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial.
Clin Cancer Res
; 29(24): 5069-5078, 2023 12 15.
Article
in English
| MEDLINE | ID: mdl-37792433
18.
"Default" generation of neonatal regulatory T cells.
J Immunol
; 185(1): 71-8, 2010 Jul 01.
Article
in English
| MEDLINE | ID: mdl-20498359
19.
Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial.
BMJ Open
; 12(11): e065109, 2022 Nov 14.
Article
in English
| MEDLINE | ID: mdl-36375974
20.
NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome.
J Immunother Cancer
; 10(6)2022 06.
Article
in English
| MEDLINE | ID: mdl-35768164